Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer
Authors:
Open Access
- 19 March 2024
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 238-247
Abstract
Https://doi.org/10.18632/oncotarget.28567 Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, Akshara Singareeka Raghavendra, Clinton Yam, Lumarie Santiago, Beatriz E. Adrada, Padmanee...Keywords
This publication has 25 references indexed in Scilit:
- LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancerAnnals of Oncology, 2023
- LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)Annals of Oncology, 2023
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialThe Lancet, 2020
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialThe Lancet, 2020
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast CancerJAMA Oncology, 2020
- Prevalence and mutational determinants of high tumor mutation burden in breast cancerAnnals of Oncology, 2020
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapyThe Lancet Oncology, 2018
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyBreast Cancer Research and Treatment, 2017
- viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemiaNature Biotechnology, 2013
- Normalization of mass cytometry data with bead standardsCytometry Part A, 2013